The Future of Microbiome Modulation Immuno-Oncology

Fabio Grassi, Founder at MV BioTherapeutics SA, discussed how to understand the mechanisms of action for microbiome contributions to cancer therapeutic response in patients.

Industry, Oncology, Video

During the Microbiome Connect: USA 2022 congress, held last November in Boston, MicrobiomePost discussed with Fabio Grassi, Founder at MV BioTherapeutics SA and Group Leader at Institute for Research in Biomedicine (Bellinzona) about how to optimize existing medicines by examining the latest clinical trials and research into microbiome modulation and response rates and how to understand the mechanisms of action for microbiome contributions to cancer therapeutic response in patients.

Staff editor

Most recent

Scientific research

HCPs Area

World Microbiome Day 2023: Microbes and Food

Probiotics for female indications: Impact of Probi® probiotics for bone health support

Industry

Freya Biosciences secures $10.4 million investment to tackle women’s health challenges

Probiotics as adjuvant therapy in cancer immunotherapy: from Biofarma Group

Read more about Industry, Oncology, Video

Nutrition

The Future of Microbiome Modulation Immuno-Oncology

Most recent

Understanding the gut microbiota in athletes

Microbial signatures for food traceability: ensuring quality and safety from fermented wines to novel insect-based foods

Freya Biosciences secures $10.4 million investment to tackle women’s health challenges

Probiotics as adjuvant therapy in cancer immunotherapy: from Biofarma Group

HCPs Area

World Microbiome Day 2023: Microbes and Food

Probiotics for female indications: Impact of Probi® probiotics for bone health support

Industry

Freya Biosciences secures $10.4 million investment to tackle women’s health challenges

Probiotics as adjuvant therapy in cancer immunotherapy: from Biofarma Group

Microbial signatures for food traceability: ensuring quality and safety from fermented wines to novel insect-based foods

Freya Biosciences secures $10.4 million investment to tackle women’s health challenges

Probiotics as adjuvant therapy in cancer immunotherapy: from Biofarma Group

QIAGEN and McGill University partner to drive innovation in microbiome research

Dietary fiber, bloutia, and mucus function: uncovering potential for Next-Generation Probiotics

EnteroBiotix’s EBX-102 shows promising Phase 1b results for liver cirrhosis treatment

October 2024 review: M&A, licensing, and investments in one place

The impact of food additives on the microbiome: pathways to personalized health